Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to findings published in the New England journal and medicine. Dr. Roshini ...

I'm in London, and I just paid for this damn fat drug I take. I said, it's not working. They said, he said, I just paid $88 ...

Hello, and welcome to Virtual Investor Conferences . On behalf of the Life Sciences Investor Forum and our co-host Zacks Small Cap Research, we're very pleased you joined us for our quarterly ...

Novo Nordisk has brought Wegovy, its once-a-week anti-obesity injection, to India starting at a price of ₹4,336.25— adding a ...

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...

Ethan Hunt's last mission? A new Superman? Happy Gilmore as a dad? Three genre-spanning Pedro Pascal movies, including a ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...